Who is Eligible for Tamiflu
Tamiflu (oseltamivir) is FDA-approved for treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days, and for prophylaxis in patients 1 year and older. 1
Treatment Eligibility
Priority Patients Who Should Receive Treatment
Regardless of vaccination status or time since symptom onset, treatment should be offered as early as possible to:
- Any hospitalized child or adult with clinically presumed influenza or severe, complicated, or progressive illness 2, 3
- Patients at high risk of complications, including:
- Children younger than 2 years (at increased risk of hospitalization) 3
- Adults 65 years and older 4
- Pregnant women
- Persons with chronic medical conditions (pulmonary, cardiovascular, renal, hepatic, hematologic, metabolic disorders including diabetes)
- Immunocompromised persons
- Residents of nursing homes or long-term care facilities 4, 5
Additional Treatment Considerations
Treatment should be considered for:
- Otherwise healthy children whose siblings are younger than 6 months or have underlying medical conditions predisposing them to influenza complications 2
- Any patient with moderate-to-severe influenza who might benefit from reduced symptom duration 4
Critical Timing Point
While treatment is most effective when started within 48 hours of symptom onset, treatment after 48 hours should still be offered to patients with moderate-to-severe or progressive disease, as it has been shown to provide benefit 2, 3. This is particularly important for hospitalized patients, where observational studies demonstrate reduced mortality even when treatment begins >48 hours after symptom onset 4.
Prophylaxis Eligibility
Pre-exposure Prophylaxis (Seasonal)
Prophylaxis should be administered for the duration of influenza season to:
- Adults and children ≥3 months at very high risk of complications for whom vaccination is contraindicated, unavailable, or expected to have low effectiveness (e.g., severely immunocompromised persons, hematopoietic stem cell transplant recipients in first 6-12 months post-transplant, lung transplant recipients) 5
Short-term prophylaxis can be considered for:
- Unvaccinated high-risk patients when influenza activity is detected in the community (given in conjunction with prompt vaccination) 5
- Unvaccinated healthcare personnel and children ≥3 months in close contact with high-risk persons during influenza activity 5
Post-exposure Prophylaxis
Prophylaxis should be given as soon as possible after exposure (ideally within 48 hours) to:
- Asymptomatic adults and children ≥3 months at very high risk of complications after household exposure 5
- Unvaccinated household contacts of persons at very high risk of complications (in conjunction with vaccination) 5
Studies demonstrate 89% protective efficacy for individuals and 84% for households when oseltamivir prophylaxis is given within 48 hours of exposure 6. In vaccinated frail elderly populations, 6-week prophylaxis showed 92% reduction in laboratory-confirmed influenza 7.
Age-Specific Eligibility
Infants Under 1 Year
FDA approval exists for treatment in patients as young as 2 weeks 2, 1. Based on preliminary pharmacokinetic and limited safety data:
- Term infants 0-8 months: 3 mg/kg/dose twice daily for treatment 2
- Infants 9-11 months: 3.5 mg/kg/dose twice daily for treatment 2
- Prophylaxis in infants 3-8 months: 3 mg/kg/dose once daily 2
- Prophylaxis in infants <3 months: Not recommended unless situation judged critical due to limited safety data 2, 8
Premature Infants
Current weight-based dosing is not appropriate for premature infants due to immature renal function and risk of very high drug concentrations. Very limited data suggest 1 mg/kg twice daily may be appropriate, but insufficient evidence exists for specific dosing recommendations 8.
Children 1 Year and Older
Weight-based dosing applies 1:
- <15 kg: 30 mg twice daily (treatment) or once daily (prophylaxis)
- 15-23 kg: 45 mg twice daily or once daily
- 23-40 kg: 60 mg twice daily or once daily
40 kg: 75 mg twice daily or once daily
Adults and Adolescents 13 Years and Older
Standard dose: 75 mg twice daily for treatment (5 days) or once daily for prophylaxis (≥10 days) 1
Special Populations Requiring Dose Adjustment
Renal Impairment
For creatinine clearance 10-30 mL/min:
- Treatment: 75 mg once daily for 5 days 2, 1
- Prophylaxis: 30 mg once daily OR 75 mg every other day for 10 days 2, 1
Recent evidence suggests current dose reductions for mild-to-moderate renal impairment may delay therapeutic concentrations and reduce efficacy 9. The first dose should be 75 mg with subsequent doses reduced proportionally.
Elderly Patients
No dose reduction based on age alone, though renal function should be assessed as it declines with age 10, 11
Important Limitations and Caveats
- Not a substitute for annual influenza vaccination 1
- No evidence of efficacy for illness caused by agents other than influenza A and B 1
- Efficacy not established when treatment begins >48 hours after symptom onset in controlled trials, though observational data support benefit 1
- Resistance patterns must be considered: During 2014-2015, all H3N2 and B viruses were sensitive to oseltamivir, but only 98.4% of pH1N1 were sensitive 2. High resistance to amantadine/rimantadine exists 2
- Prophylaxis is not a substitute for vaccination but serves as an important adjunct 12, 13
Common Pitfall to Avoid
Do not withhold treatment from hospitalized or high-risk patients simply because >48 hours have elapsed since symptom onset. Multiple observational studies demonstrate mortality benefit even with delayed treatment initiation 4, 3, 14.